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Introduction: Recent studies examining the association of Toll-like receptor 3 (TLR3) gene polymorphisms with the
risk of developing various types of cancer have reported conflicting results. Clarifying this association could advance
our knowledge of the influence of TLR3 single nucleotide polymorphisms (SNPs) on cancer risk.
Methods: We systematically reviewed studies that focused on a collection of 12 SNPs located in the TLR3 gene and
the details by which these SNPs influenced cancer risk. Additionally, 14 case-control studies comprising a total of
7997 cases of cancer and 8699 controls were included in a meta-analysis of 4 highly studied SNPs (rs3775290,
rs3775291, rs3775292, and rs5743312).
Results: The variant TLR3 genotype rs5743312 (C9948T, intron 3, C > T) was significantly associated with an
increased cancer risk as compared with the wild-type allele (odds ratio [OR] = 1.11, 95 % confidence interval
[CI] = 1.00–1.24, P = 0.047). No such association was observed with other TLR3 SNPs. In the stratified analysis, the
rs3775290 (C13766T, C > T) variant genotype was found to be significantly associated with an increased cancer risk
in Asian populations. Additionally, the rs3775291 (G13909A, G > A) variant genotype was significantly associated with
an increased cancer risk in Asians, subgroup with hospital-based controls, and subgroup with a small sample size.
Conclusion: After data integration, our findings suggest that the TLR3 rs5743312 polymorphism may contribute to an
increased cancer risk.
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Toll-like receptors (TLRs) are members of a membrane
receptor protein family that recognize the antigenic deter-
minants of viruses, bacteria, protozoa, and fungi, and are
thus associated with immunity. There are two pathways
associated with the immune deficiencies that lead to dis-
ease: the MyD88-IRAK4 pathway, involving all TLR family
proteins except TLR3, and the TLR3-Unc93b-TRIF-
TRAF3 pathway [1, 2]. Therefore, TLR3 can be considered
a unique protein in the TLR family, and it has been further
implicated in the development of tumors resulting from
an activated immune system.
TLR3 single nucleotide polymorphisms (SNPs) could
possibly affect cancer susceptibility and could therefore
serve as potential biomarkers to evaluate cancer risk [3].* Correspondence: liuyongfengsubmit@163.com
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(http://creativecommons.org/publicdomain/zeThus, TLR3 polymorphisms that are associated with
both heredity and environmental factors may be critical
in bridging the relationship between genetic factors and
external environmental conditions. TLR3 SNPs were
originally identified by He et al. [4] in 2007. Since then,
several studies have focused on examining the association
of TLR3 SNPs with cancer risk. However, the first studied
SNP site included 10 SNPs covering the entire TLR3 gene,
and because each of these SNPs had several reported
names, confusion arose in the literature. Furthermore,
published results of the TLR3 gene have been conflicting.
The TLR3 SNPs that exhibit the most variability are
rs3775290 and rs3775291; however, their relationship with
cancer risk remains unclear. For instance, although the
majority of studies have reported that the rs3775290 vari-
ant T allele was associated with an increased cancer risk
(odds ratio [OR] > 1), four studies testing this conclusion
did not reach statistical significance (P > 0.05) [5–8] andicle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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(P < 0.05) [9]. Furthermore, another study reported the
opposite result that the variant allele was associated with a
decreased cancer risk (OR = 0.88) [4]. Thus, a comprehen-
sive analysis integrating all studies on TLR3 SNPs and
cancer risk is needed. In addition, no systematic review or
meta-analysis for the TLR3 gene polymorphisms has been
performed.
Here, we systematically reviewed published data and
comprehensively analyzed and integrated all published
studies on the relationship between TLR3 SNPs and can-
cer risk. We also contacted the authors of these studies
to obtain any data that was omitted from published arti-
cles so as to enhance our comprehension of the details
surrounding these SNPs. We included a meta-analysis
for hotspot SNPs (rs3775290, rs3775291, rs3775292, and
rs5743312) that have been described in at least three
published studies to enhance the comprehensiveness of




A systematic literature search was performed on the associ-
ation between the TLR3 rs3775290, rs3775291, rs3775292,
rs5743312 polymorphisms and cancer risk. Our final search
concluded with literature published on or before October
5th, 2014. Two independent researchers (Ben-Gang Wang
and De-Hui Yi) searched the PubMed, Chinese National
Knowledge Infrastructure (CNKI), and Web of Science da-
tabases for the following keywords: “TLR3,” “cancer/carcin-
oma/tumor/neoplasm,” and “polymorphism”. The inclusion
criteria were as follows: (1) case-control studies, (2) studies
evaluating the association between TLR3 polymorphisms
and cancer risk, and (3) the SNP was reported in at least 3
publications. The major exclusion criteria were as follows:
(1) studies that presented duplicate data, (2) studies that
included only cancer patients (i.e., no healthy controls),
and (3) studies that investigated benign diseases compared
with controls.
Data extraction
Two independent researchers (Ben-Gang Wang and
De-Hui Yi) each extracted all data that were considered
to be relevant, and in cases of inconsistent selection, a
third author (Yong-Feng Liu) participated in data selec-
tion. In this way, a consensus was reached on which
studies should be included for analysis. For each study,
the following items were collected: first author’s name,
publication year, country of origin, ethnicity, cancer type,
source of control groups (population- or hospital-based),
genotyping method, total numbers of cases and controls,
and genotype distributions in cases and controls. When
we considered the published data to be insufficient forour analyses, we contacted the authors to obtain the
original data. Thus, the data included in this review were
obtained from both published and unpublished studies.
Statistical analyses
The Chi-square test was used to determine the Hardy-
Weinberg equilibrium (HWE) for the genotype frequencies
of different TLR3 polymorphisms; a result of P < 0.05 was
considered to indicate significant disequilibrium. The
strength of the association between TLR3 polymorphisms
and cancer risk was calculated using odds ratios (ORs) with
95 % confidence intervals (CIs). The heterogeneity between
different studies was calculated using the Cochran’s Q test
and quantified by the I2 (a significance level of P < 0.10).
When heterogeneity did not exist, a fixed-effect model
based on the Mantel-Haenszel method was used to assess
the pooled OR of each study [10]. When heterogeneity did
exist, a random-effect model based on the method devel-
oped by DerSimonian and Laird was employed [11]. Five
comparison models were evaluated: heterozygote compari-
son (M1: Aa vs. AA), homozygote comparison (M2: aa vs.
AA), dominant model (M3: Aa + aa vs. AA), recessive
model (M4: aa vs. AA +Aa), and allelic model (M5: a vs.
A). “A” indicates wild allele, and “a” indicates variant allele.
OR1 and OR2 were calculated for the genotypes aa vs. AA
(M2) and Aa vs. AA (M1), and were used to determine the
most appropriate genetic model. According to the refer-
ence [12], a recessive model is recommended in cases
where OR1 ≠ 1 and OR2 = 1, whereas a dominant model is
suggested for cases in which OR1 =OR2 ≠ 1, and a codomi-
nant model is indicated if OR1 >OR2 > 1 or OR1 <OR2 < 1.
For studies with sufficient patients, we also performed
stratification analyses on cancer type, ethnicity (Asian or
Caucasian), sources of controls (population- or hospital-
based study design), and sample size (total samples ≥1000
[large sample size] or <1000 [small sample size]). The
Begg’s rank correlation and the Egger’s linear regression
tests were used to evaluate publication bias [13, 14]. A
value of P < 0.10 was considered statistically significant.
All analyses were performed using STATA software, ver-
sion 11.0 (STATA Corp., College Station, TX, USA).
Results
Characteristics of the included studies
Searches of the PubMed, CNKI, and Web of Science
databases using different combinations of our keywords
yielded a total of 155 records (after duplicates were re-
moved). We excluded 50 studies based on the information
presented in the title or abstract (17 were irrelevant arti-
cles, 16 were functional studies rather than polymorphism
studies, and 17 were review articles) and 91 studies based
on the information presented in the text (5 were not case-
control studies, 62 were not about TLR3 gene polymor-
phisms, and 24 were not relevant to cancer). Thus, a total
Table 1 The studies included in this systematic review for the association between Toll-like receptor 3 (TLR3) single nucleotide polymorphisms (SNPs) and the risk of developing cancer
Publication year Study Country Sample size Source of controls Genotyping method Matched factors Adjusted factors
Cases Controls
2007 He et al. [4] China 434 512 Population-based Sequencing Sex and age matched None
2009 Etokebe et al. [8] Croatia 130 101 Population-based qPCR All females, age not matched None
2010 Lei et al. [15] China 981 1221 Population-based SNP Stream All females, age matched Age and BMI
2011 Pandey et al. [7] India 200 200 Not mentioned, only healthy controls PCR-RFLP All females, age matched Age
Gast et al. [16] Germany 763 736 Hospital-based Two multiplex PCR Sex not mentioned, age not matched None
2012 Mandal et al. [6] India 195 250 Hospital-based PCR-RFLP All males, age matched
Slattery et al.[17] USA 2309 2915 Population-based Multiplexed bead array Sex and age matched None
2013 Singh et al. [5] India 200 200 Hospital-based PCR-RFLP Sex and age matched Age, sex, and smoking
Li et al. [9] China 466 482 Population-based PCR-RFLP Sex and age matched Sex and age
Resler et al. [18] USA 840 800 Population-based Chip All females, age matched Age
Zeljic et al. [19] Yugoslavia 93 104 Not mentioned, only healthy controls qPCR Sex and age matched Sex, age, smoking, and
alcohol consumption
Yeyeodu et al. [20] USA 102 72 Hospital-based SNP Stream All females, age not mentioned None
Moumad et al. [21] Germany 472 362 Hospital-based KASPar Sex and age matched Sex and age
2014 Zidi et al. [22] Tunisia 130 200 Hospital-based PCR-RFLP All females, age not matched None












Table 2 The associations between TLR3 polymorphisms and
cancer risk in the 14 selected studies
TLR3 SNP Location Association(s) with tumor(s)
rs10025405 3′-near gene Breast cancer, associated [20]
rs11721827 Intron 1 Nasopharyngeal carcinoma, associated [4]
Colorectal cancer, associated [17]
rs11730143 Intron 1 Melanoma, not associated [16]
rs13126816 Intron 1 Melanoma, not associated [16]
rs3775290 Exon 4 Nasopharyngeal carcinoma,
not associated [4]
Bladder cancer, not associated [5]
Prostate cancer, not associated [6]
Cervical cancer, not associated [7]
Breast cancer, not associated [8]
Cervical cancer, associated [22]
rs3775291 Exon 4, L412F Nasopharyngeal carcinoma,
not associated [4]
Hepatocellular carcinoma, associated [9]
Breast cancer, not associated [15]
Melanoma, not associated [16]
Colorectal cancer, not associated [17]
Breast cancer, not associated [18]
Oral cancer, associated [19]
Nasopharyngeal carcinoma, associated [21]
rs3775292 Intron 3 Melanoma, not associated [16]
Colorectal cancer, associated [17]
Breast cancer, not associated [18]
rs5743305 5′-near gene Hepatocellular carcinoma, not associated [9]
Colorectal cancer, not associated [17]
rs5743312 Intron 3 Nasopharyngeal carcinoma,
not associated [4]
Melanoma, not associated [16]
Oral cancer, associated with survival [19]
rs7657186 Intron 1 Melanoma, not associated [16]
Breast cancer, not associated [20]
rs7668666 Intron 3 Melanoma, not associated [16]
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were included in our systematic review and final meta-
analysis, which consisted of 7997 cancer patients and 8699
cancer-free controls [4–9, 15–22] (Table 1).
Of the 14 enrolled studies, all but 4 were matched by
age; 6 were sex-matched, 1 did not mention the sex-
matching, and 7 that examined either breast, cervical, or
prostate cancer did not need to match for sex. Six studies
investigated Asians, 7 investigated Caucasians, and 1 was
conducted in Africa. The controls were hospital-based in 6
studies, population-based in 6 studies, and not mentioned
in 2 studies. Genotyping methods included polymerase
chain reaction-restriction fragment length polymorphism
(PCR-RFLP, 5 studies), quantitative polymerase chain reac-
tion (qPCR, 2 studies), Chip (1 study), multiplexed bead
array (1 study), two multiplex PCR (1 study), the KASPar
SNP genotyping system (1 study), SNP Stream (2 studies),
and sequencing (1 study). Eight studies checked genotypes
for quality control [4–6, 9, 16–18, 21]. The genotype distri-
bution of controls was consistent with the Hardy-Weinberg
equilibrium model in all but four studies [9, 15, 17, 22].
In these 14 studies, 12 SNPs were reported. Table 2 lists
the SNP locations, studied tumor types, and any associa-
tions between TLR3 SNPs and cancer risk. In summary,
there are 10 types of cancer that have been evaluated in
relation to TLR3 SNPs. The majority of the 12 SNPs
located within an intronic region of the TLR3 gene, except
for 2 that were found in the 3′ and 5′ regions of the gene
and another 2 that located within exons. Only 4 SNPs
(rs3775290, rs3775291, rs3775292, and rs5743312) were
reported in at least 3 studies. For this reason, we defined
them as hotspot SNPs which covered all 10 cancer types
included in this study (Table 3).
Unpublished data obtained from the original authors
Slattery et al. [17] detected TLR3 rs3775291 and rs377
5292 SNPs in colorectal cancer patients and showed only
the minimum allele frequency for these SNPs. We
contacted the authors of this study to obtain the genotype
information of these two SNPs that were found in the case
and control groups, and we were especially interested in
the results when dividing patients into colon cancer and
rectal cancer groups. These results are presented in bold
in Table 3.
Quantitative synthesis
The variant T allele of the rs5743312 SNP was significantly
associated with an increased risk of cancer when com-
pared with the wild C allele (OR = 1.11, 95 % CI = 1.00–
1.24, P = 0.047) (Table 4, Fig. 1a). The OR1 and OR2
values of this rs5743312 SNP were 1.88 (P < 0.001) and
1.02 (P = 0.832), respectively. Thus, a codominant model
(M2) was the most appropriate choice for rs5743312.
Regardless of the genetic model, no other TLR3 SNPs(rs3775290, rs3775291, and rs3775292) were found to be
associated with cancer risks.
In the stratified analysis, the rs3775290 variant genotype
was significantly associated with an increased cancer risk
in Asian populations in M1 (CT vs. CC: OR = 1.28, 95 %
CI = 1.02–1.62, P = 0.036), M2 (TT vs. CC: OR = 1.79,
95 % CI = 1.05–3.05, P = 0.032), and M3 models (CT + TT
vs. CC: OR = 1.33, 95 % CI = 1.06–1.67, P = 0.013) (Table 5,
Fig. 1b). For the rs3775291 SNP, both the GA heterozy-
gote and the GA+AA genotypes were consistently associ-
ated with an increased risk of nasopharyngeal cancer (GA
vs. GG: OR = 1.54, 95 % CI = 1.14–2.09, P = 0.005; GA +
Table 3 Characteristics of the 14 studies included for this meta-analysis
Study Ethnicity Cancer type Sample size Cases Controls P of
HWECase Control wt/wt wt/var var/var wt/wt wt/var var/var
rs3775290 (C13766T, C > T)
He et al. [4] Asian Nasopharyngeal carcinoma 395 371 565* 225* 510* 232a
Singh et al. [5] Asian Bladder cancer 200 200 106 81 13 122 71 7 0.391
Mandal et al. [6] Asian Prostate cancer 195 250 115 68 12 157 84 9 0.585
Pandey et al. [7] Asian Cervical cancer 200 200 91 98 11 110 81 9 0.217
Etokebe et al. [8] Caucasian Breast cancer 130 101 58 56 14 46 42 8 0.713
Zidi et al. [22] Caucasian Cervical cancer 130 200 69 48 13 76 106 18 0.026
rs3775291 (G13909A, L412F, G > A)
He et al. [4] Asian Nasopharyngeal carcinoma 333 287 405* 261* 359a 215a
Li et al. [9] Asian Hepatocellular carcinoma 466 482 192 222 52 256 203 23 0.030
Lei et al. [15] Asian Breast cancer 981 1221 447 431 103 594 500 127 0.155
Gast et al. [16] Caucasian Skin malignant melanoma 732 668 379 291 62 332 284 52 0.415
Slattery et al. [17] Caucasian Colon cancer 1554 1955 748 653 153 947 817 191 0.446
Rectal cancer 754 959 363 332 59 478 381 100 0.066
Resler et al. [18] Caucasian Breast cancer 840 801 427 348 65 418 318 65 0.679
Zeljic et al. [19] Caucasian Oral squamous cell carcinomas 93 104 39 39 15 43 53 8 0.128
Moumad et al. [21] African Nasopharyngeal carcinoma 472 362 289 170 13 252 96 14 0.210
rs3775292 (C/G, intron 3, C > G)
Gast et al. [16] Caucasian Skin malignant melanoma 730 668 464 233 33 413 228 27 0.521
Slattery et al. [17] Caucasian Colon cancer 1554 1956 990 507 57 1253 601 102 0.008
Rectal cancer 754 959 494 222 38 586 335 38 0.247
Resler et al. [18] Caucasian Breast cancer 840 800 522 284 34 509 262 29 0.507
rs5743312 (C9948T, intron 3, C > T)
He et al. [4] Asian Nasopharyngeal carcinoma 405 200 640* 170a 316* 84a
Lei et al. [15] Asian Breast cancer 996 1245 582 348 66 770 433 42 0.044
Gast et al. [16] Caucasian Skin malignant melanoma 716 657 500 200 16 453 193 11 0.060
Zeljic et al. [19] Caucasian Oral squamous cell carcinomas 93 104 69 21 3 78 24 2 0.923
wt/wt, wild type/wild type, indicating wild genotype; wt/var, wild type/variant type, indicating heterozygote; var/var, variant type/variant type, indicating variant
genotype; HWE, Hardy-Weinberg equilibrium. *Only the data of allelic model were available, and thus the studies were analyzed only when the allelic model
was used. The bold means the genotype information of the rs3775291 and rs3775292 SNPs that readers could not found in [17], and these data were kindly
provided by the contacted authors.
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(Table 5, Fig. 1c1). When the data were stratified by eth-
nicity, the GA heterozygote was significantly associated
with an increased cancer risk in the Asian subgroup (GA
vs. GG: OR = 1.27, 95 % CI = 1.00–1.60, P = 0.048) (Table 5,
Fig. 1c2). When the data were stratified by the source of
controls, the hospital-based subgroup showed that the
variant allele was significantly associated with an increased
cancer risk (GA vs. GG: OR = 1.50, 95 % CI = 1.23–1.83,
P < 0.001; GA+AA vs. GG: OR = 1.54, 95 % CI = 1.27–
1.87, P < 0.001; A vs. G: OR = 1.43, 95 % CI = 1.23–1.67,
P < 0.001) (Table 5, Fig. 1c3). Finally, when the data were
stratified by sample size, the small sample size subgroup
showed that the variant genotype was significantly associ-
ated with an increased cancer risk (AA vs. GG: OR = 2.77,95 % CI = 1.75–4.39, P < 0.001; AA vs. GA +GG: OR =
2.46, 95 % CI = 1.58–3.83, P < 0.001) (Table 5, Fig. 1c4).Heterogeneity
The heterogeneities that originated within the collection
of selected studies and within each subgroup of studies
are shown in Tables 4 and 5, respectively. Slight hetero-
geneities were found when comparing different studies.
To explore the influence of individual studies on the
pooled results, we analyzed the sensitivity of our meth-
odology by removing one study at a time from the
pooled analyses. No significant heterogeneity was found
for any genetic model, which suggested that our results
were relatively reliable.
Table 4 Pooled ORs and 95 % CIs of TLR3 polymorphisms in this meta-analysis
SNP Number
of studies
M1 M2 M3 M4 Number
of studies
M5
OR (95 % CI) P I2 (%) OR (95 % CI) P I2 (%) OR (95 % CI) P I2 (%) OR (95 % CI) P I2 (%) OR (95 % CI) P I2 (%)
rs3775290 (C13766T, C > T) 5 1.04 0.854* 70.0 1.38 0.110 0.0 1.09 0.640* 69.4 1.41 0.082 0.0 6 1.06 0.550 59.3
(0.72-1.49) (0.93-2.06) (0.77-1.53) (0.96-2.08) (0.87-1.30)
rs3775291 (G13909A,
L412F, G > A)
8 1.12 0.056* 53.9 1.13 0.335* 66.5 1.12 0.054* 58.6 1.08 0.507* 65.2 9 1.09 0.064* 59.5
(1.00-1.26) (0.88-1.45) (1.00-1.26) (0.86-1.37) (1.00-1.19)
rs3775292 (C/G, intron 3,
C > G)
4 0.96 0.554* 54.5 0.93 0.500 34.7 0.97 0.476 23.1 0.94 0.554 49.9 4 0.97 0.416 0.0
(0.83-1.11) (0.75-1.15) (0.89-1.06) (0.76-1.16) (0.90-1.05)
rs5743312 (C9948T,
intron 3, C > T)
3 1.02 0.832 0.0 1.88 <0.001 0.0 1.08 0.267 0.0 1.86 <0.001 0.0 4 1.11 0.047 7.1
(0.88-1.17) (1.33-2.67) (0.94-1.23) (1.32-2.63) (1.00-1.24)
OR, odds ratio; CI, confidence interval. *The heterogeneity exists; a random-effect model based on the DerSimonian and Laird method or a fixed-effect model based on the Mantel-Haenszel method was used.
M1: Aa vs. AA, heterozygote comparison; M2: aa vs. AA, homozygote comparison; M3: Aa + aa vs. AA, dominant model; M4: aa vs. AA + Aa, recessive model; M5: a vs. A, allelic model (A indicates wild allele, a












Fig. 1 Forest plot of the odds ratios (ORs) for the association of Toll-like receptor 3 (TLR3) single nucleotide polymorphisms (SNPs) with cancer risk.
a, the association of the TLR3 rs5743312 SNP with cancer risk when stratified by ethnicity (allelic model). b, the association of the TLR3 rs3775290
SNP with cancer risk when stratified by ethnicity (dominant model). c, The association of TLR3 rs3775291 SNP with cancer risk (dominant model)
when stratified by cancer type (c1), ethnicity (c2), source of controls (c3), and sample size (c4). *The cancer type was colon cancer; #the cancer
type was rectal cancer
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Table 5 Pooled ORs and 95 % CIs of TLR3 polymorphisms in the stratified analysis
Stratification Number
of studies
M1 M2 M3 M4 Number
of studies
M5
OR (95 % CI) P I2 (%) OR (95 % CI) P I2 (%) OR (95 % CI) P I2 (%) OR (95 % CI) P I2 (%) OR (95 % CI) P I2 (%)
rs3775290 (C13766T, C > T)
Ethnicity
Asian 3 1.28 0.036 0 1.79 0.032 0 1.33 0.013 0 1.61 0.08 0 4 1.14 0.25a 58.2
(1.02-1.62) (1.05-3.05) (1.06-1.67) (0.95-2.71) (0.91-1.43)
Caucasian 2 0.72 0.372 75.5 1.00 0.996 0 0.76 0.45a 75.6 1.35 0.52 0 2 0.89 0.60a 63.6




4 0.97 0.892 75 1.26 0.3 0 1.04 0.73a 73.9 1.33 0.2 0 1.07 0.64a 58.8
(0.62-1.53) (0.81-1.95) (0.84-1.29) (0.87-2.03) (0.82-1.39)
Source of controls
Hospital-based NA NA NA NA 5 1.12 0.32a 54.7
(0.90-1.40)
Population-based NA NA NA NA 1 0.88 0.23
(0.70-1.09)
rs3775291 (G13909A,
L412F, G > A)
Cancer type
Digestive tract cancer 3 1.16 0.132a 65.4 1.28 0.429 89.1 1.18 0.186 80.4 1.18 0.559a 87.4 3 1.14 0.288a 87.5
(0.96-1.41) (0.69-2.38) (0.92-1.51) (0.68-2.05) (0.90-1.44)
Breast cancer 2 1.11 0.118 0 1.04 0.739 0 1.10 0.148 0 0.99 0.911 0 2 1.05 0.288 0
(0.97-1.27) (0.70-1.55) (0.97-1.25) (0.79-1.23) (0.96-1.16)
Nasopharyngeal
carcinoma
1 1.54 0.005 0.81 0.593 1.45 0.012 0.70 0.37 2 1.16 0.083 0
(1.14-2.09) (0.37-1.76) (1.09-1.94) (0.33-1.52) (0.98-1.37)
Ethnicity
Caucasian 5 1.02 0.613 0 0.98 0.78 4.6 1.02 0.732 0 0.97 0.685 40.9 5 1.00 0.94 0
(0.94-1.12) (0.84-1.14) (0.93-1.11) (0.84-1.13) (0.93-1.07)
Asian 2 1.27 0.048a 54 1.76 0.272 91.2 1.33 0.105 80.7 1.55 0.334 89.5 3 1.21 0.108a 79.5
(1.00-1.60) (0.64-4.82) (0.94-1.89) (0.64-3.77) (0.96-1.53)
African 1 1.23 0.005 0.81 0.593 1.45 0.012 0.70 0.37 1 1.27 0.062












Table 5 Pooled ORs and 95 % CIs of TLR3 polymorphisms in the stratified analysis (Continued)
Source of controls
Hospital-based 2 1.50 <0.001 0 1.61 0.466a 86.8 1.54 <0.001 0 1.37 0.616a 86.3 2 1.43 <0.001 32.6
(1.23-1.83) (0.45-5.84) (1.27-1.87) (0.40-4.76) (1.23-1.67)
Population-based 6 1.05 0.259 0 1.00 0.999 0 1.04 0.338 0 0.98 0.748 26.9 7 1.02 0.465a 0
(0.97-1.14) (0.87-1.15) (0.96-1.12) (0.86-1.12) (0.97-1.08)
Sample size
Large 5 1.05 0.218 0 0.98 0.823 0 1.04 0.328 0 0.96 0.545 0 5 1.02 0.629 0
(0.97-1.14) (0.86-1.13) (0.96-1.12) (0.84-1.10) (0.96-1.08)
Small 3 1.41 <0.001 45.6 1.76 0.184a 73.7 1.47 <0.001 21.1 1.63 0.242a 73.9 4 1.30 <0.001 47.9




Colorectal cancer 2 0.93 0.609a 82.2 0.89 0.657a 68 0.93 0.464a 63.8 0.92 0.797a 78.2 2 0.94 0.233 0
(0.69-1.25) (0.54-1.48) (0.76-1.13) (0.50-1.69) (0.86-1.04)
Breast Cancer 1 1.06 0.601 1.14 0.607 1.07 0.535 1.12 0.656 1 1.06 0.499
(0.86-1.30) (0.69-1.90) (0.87-1.30) (0.68-1.86) (0.90-1.26)
Skin malignant
melanoma
1 0.91 0.411 1.09 0.753 0.93 0.503 1.12 0.659 1 0.96 0.683
(0.73-1.14) (0.64-1.84) (0.75-1.15) (0.67-1.89) (0.80-1.16)
rs5743312 (C9948T,
intron 3, C > T)
Ethnicity
Asian NA NA NA NA 2 1.17 0.017 25.3
(1.03-1.33)
Caucasian NA NA NA NA 2 0.99 0.995 0
(0.83-1.21)
Sample size
Large 2 1.02 0.82 0 1.89 <0.001 4 1.08 0.268 37.2 1.87 0.001 0 2 1.11 0.305a 61.7
(0.88-1.17) (1.32-2.70) (0.94-1.24) (1.31-2.65) (0.99-1.24)
Small 1 0.99 0.97 1.70 0.569 1.04 0.9 1.70 0.566 2 1.02 0.894 0
(0.51-1.93) (0.28-10.45) (0.55-1.98) (0.28-10.40) (0.78-1.32)
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The Begg’s rank correlation and Egger’s linear regression
tests were conducted to evaluate publication bias. Ac-
cording to the results of these tests, a slight publication
bias for rs3775290 in M2 was indicated (Table 6).
Discussion
In this meta-analysis, we found that TLR3 rs5743312 was
associated with an increased overall risk of developing
cancer. This was also true for the large sample size
subgroup. TLR3 rs3775290 and rs3775291 polymorphisms
were found to be associated with increased cancer risks in
the stratified analysis, whereas no association was found
between TLR3 rs3775292 and cancer risk.
The TLR3 rs5743312 polymorphism is located in intron
3, and no previous studies have shown any association be-
tween this polymorphism and cancer risk. However, after
data integration, we concluded that this SNP is the only
significant site in the TLR3 gene with respect to cancer
risk. According to our meta-analysis, the remaining 3Table 6 The results of Begg’s and Egger’s test for the
publication bias
Comparison model Begg’s test Egger’s test
Z value P value t value P value
rs3775290 (C13766T, C > T)
M1 −0.98 0.327 −0.88 0.443
M2 0.98 0.327 3.08 0.054
M3 −0.98 0.327 −0.78 0.493
M4 1.47 0.142 1.7 0.188
M5 −0.19 0.851 0.87 0.432
rs3775291 (G13909A, L412F, G > A)
M1 0.49 0.621 0.62 0.559
M2 0.99 0.322 1.06 0.329
M3 0.49 0.621 1.02 0.346
M4 0.99 0.322 1.02 0.348
M5 1.25 0.211 1.48 0.183
rs3775292 (C/G, intron 3, C > G)
M1 −1.36 0.174 −1.14 0.371
M2 0.00 1.000 3.88 0.061
M3 0.00 1.000 −0.68 0.567
M4 0.00 1.000 3.11 0.090
M5 0.68 0.497 0.14 0.901
rs5743312 (C9948T, intron 3, C > T)
M1 −0.52 0.602 −0.39 0.764
M2 −0.52 0.602 −0.76 0.587
M3 −0.52 0.602 0.75 0.590
M4 −0.52 0.602 −0.75 0.589
M5 0.00 1.000 −0.86 0.479
NA, not available. Other footnotes as in Table 4.SNPs exhibited no association with cancer risks. The sub-
group analyses for the rs5743312 SNP showed the same
tendency as the whole group analysis. Previous studies
have suggested that intronic SNPs may exhibit specific
functions, such as directing alternative splicing [23, 24].
As intronic polymorphisms have been shown to exhibit
critical functions, it would be prudent to include intronic
SNPs, such as rs5743312, in future studies.
rs3775290 is located in exon 4 of the TLR3 gene and is
also a hotspot TLR3 SNP. In our stratification analyses,
TLR3 rs3775290 was found to be associated with cancer
risk in Asian populations. This may be due to the variabil-
ity in genetic background between Asians and Caucasians
(Fig. 2). In the HapMap database, rs3775290 showed a ra-
tio of 0.217:0.783 for the wild-type A:variant G allele in
the HapMap-CEU population and of 0.408:0.592 for the
A:G allele in the HapMap-CHB and HapMap-JPT popula-
tions (http://www.ncbi.nlm.nih.gov/SNP/snp_ref.cgi?rs=37
75290). Variations in ethnic backgrounds play an import-
ant role in genetic susceptibility, and genetic differences
between Asians and Caucasians may be the reason that
these different ethnic populations follow different life styles
and are thus exposed to different environmental factors
[25]. Population groups that are carrying different geno-
types or allele frequencies of the rs3775290 polymorphism
may show differences in cancer susceptibility [26]. The C
to T variant of rs3775290 results in a silent mutation in
phenylalanine residue 459. When a SNP leads to a silent
mutation, it does not necessarily indicate that the SNP has
no impact on protein dynamics. For example, a silent mu-
tation located in an exon might affect interactions between
genetic elements and additional molecules, such as metal
ions or transcription factors [27].
To date, the rs3775291 polymorphism has been the
most investigated SNP in TLR3. In the stratified analysis,
TLR3 rs3775291 was also found to be associated with can-
cer risk in Asians in a heterozygote model (Table 5). Fur-
thermore, when examining our findings on a subgroup-
by-subgroup basis, we found that the small sample size
subgroup showed that rs3775291 was associated with a
significantly increased cancer risk in the M2 and M4
models, whereas the hospital-based subgroup showed this
association in the M1, M3, and M5 models. These find-
ings may have arisen because the 3 corresponding studies
each obtained significant results. It is possible that in the
Asian subgroup, the rs3775291 SNP was associated with
cancer risks due to differences in genetic and environ-
mental backgrounds between Asians and Caucasians. In
the subgroup analyses, we found a significant associ-
ation in the small sample size subgroup but not in the
large sample size subgroup. In the large sample size
subgroup, the ORs in the 5 included studies were all
approximately 1.0, whereas the ORs in the studies con-
ducted by Li et al. [9], Zeljic et al. [19], and Moumad
Fig. 2 The linkage disequilibrium plot of TLR3 gene polymorphisms found in individuals of different ethnicities, expanding 20 kb from 5′ to 3′
each (downloaded from the HapMap database). a, European; b, Chinese Han; c, Japanese; d, African. Different SNP distributions arise in response
to differences in ethnicity. Therefore, differences in ethnicity should be considered when designing the study. Furthermore, some TLR3 SNPs
might be in linkage disequilibrium, suggesting that a haplotype study may be more effective for predicting or screening susceptible populations
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small sample size subgroup. The same was true for the
hospital-based analysis. Reliable results could be ob-
tained in these cases based on the high quality of the
studies designed to explore the real associations of TLR3
SNPs with cancer risk. Differences in patients’ genetic or
environmental backgrounds might certainly be a common
mechanism behind the conclusions of our stratification
analysis. Differences in how studies were controlled ordocumented might also provide an explanation for these
conclusions. For example, the studies conducted by Li
et al. [9] and Moumad et al. [21] were well controlled,
which might explain why positive results were obtained
following the analysis of the small sample size subgroup.
Furthermore, rs3775291 is located in exon 4, and the G to
A variant results in the change of a leucine to phenylalanine
at residue 412, which might provide a mechanistic
explanation for the effects of this SNP.
Wang et al. Chinese Journal of Cancer  (2015) 34:19 Page 12 of 13Similar to rs5743312, rs3775292 is an intronic poly-
morphism that has also been investigated in detail, as its
location in intron 3 is near rs3775290 and rs3775291.
Thus, this polymorphism might be associated with variabil-
ity in alternative splicing and further associated with the
linkage disequilibrium between rs3775290 and rs3775291
[24]. Two of the included studies showed no association of
these SNPs with cancer risk, whereas one showed an asso-
ciation. However, our integrated meta-analysis results did
not find any association between the rs3775292 SNP and
cancer risk. Additional studies will be required to confirm
these results.
Our meta-analysis had several limitations. First, only
studies that were published in English or Chinese were
included in our analysis, thereby creating potential publi-
cation bias. Second, the pooled sample size was relatively
limited and therefore could support only preliminary
evaluations of the association between various TLR3 poly-
morphisms and the incidence of various types of cancer.
Additionally, we were not always able to obtain original
data from the published literature, such as the age and sex
of the patients, or the environmental factors that might
have affected the hosts. Thus, we used unadjusted infor-
mation, whereas a more precise analysis could be con-
ducted if detailed information on the original data were
available. Therefore, additional studies are required to im-
prove the reliability of these results.
Conclusion
In summary, this meta-analysis indicated that the vari-
ant allele of TLR3 rs5743312 is potentially associated
with increased cancer risks both in the whole collection
of studies and in the large sample size subgroup. In the
stratified analysis, the variant genotype of the TLR3
rs3775290 polymorphism was associated with an in-
creased cancer risk in the Asian subgroup. TLR3
rs3775291 was also associated with an increased cancer
risk in the Asian, hospital-based source of controls, and
small sample size subgroups. No association was found
between TLR3 rs3775292 and cancer risk. Additional
well-designed, large-scale, and functional studies on
TLR3 SNPs are required to confirm our findings.
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